Biorepository a ‘one-stop’ solution for contract biomanufacturing

By Maggie Lynch

- Last updated on GMT

(Image: Getty/sanjeri)
(Image: Getty/sanjeri)

Related tags biomanufacturing Manufacturing Contract manufacturing Contract manufacturing organisation Biologics

LakePharma opens a GMP biorepository facility to assist clients with biomanufacturing and long-term material storage.

LakePharma’s biorepository facility is part of its good manufacturing practice (GMP) microbiomanufacturing center in the Boston area. The center began operations last month and is now producing GMP-grade plasmid DNA.

A spokesperson for LakePharma, a contract research, development, and manufacturing organization (CRDMO) told us, “Since LakePharma has already established four other facilities focusing on upstream discovery and development, the next logical step is to establish a GMP facility–LakePharma’s microbiomanufacturing Center—dedicated to GMP manufacturing.”

The biorepository facility has the capabilities to store drug developers’ materials in the required temperature conditions.

LakePharma’s CEO, Hua Tu, said in a statement that the biorepository aligns itself with the company’s manufacturing services and capabilities. The biorepository extends the company’s ability to offer an end-to-end client solution, providing a “one-stop”​ solution from manufacturing to long term storage of biological materials, he said

“The market demand for cGMP services continues to expand, and LakePharma expects to participate in that growth. We will scale our manufacturing capabilities and plan on hiring an additional 50 staff this year,"​ added Tu. 

Related news

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers